Cargando…
Growth and differentiation factor 15 and NF‐κB expression in benign prostatic biopsies and risk of subsequent prostate cancer detection
Growth and differentiation factor 15 (GDF‐15), also known as macrophage inhibitory cytokine 1 (MIC‐1), may act as both a tumor suppressor and promotor and, by regulating NF‐κB and macrophage signaling, promote early prostate carcinogenesis. To determine whether expression of these two inflammation‐r...
Autores principales: | , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8085972/ https://www.ncbi.nlm.nih.gov/pubmed/33784024 http://dx.doi.org/10.1002/cam4.3850 |
_version_ | 1783686437113167872 |
---|---|
author | Rybicki, Benjamin A. Sadasivan, Sudha M. Chen, Yalei Kravtsov, Oleksandr Palangmonthip, Watchareepohn Arora, Kanika Gupta, Nilesh S. Williamson, Sean Bobbitt, Kevin Chitale, Dhananjay A. Tang, Deliang Rundle, Andrew G. Iczkowski, Kenneth A. |
author_facet | Rybicki, Benjamin A. Sadasivan, Sudha M. Chen, Yalei Kravtsov, Oleksandr Palangmonthip, Watchareepohn Arora, Kanika Gupta, Nilesh S. Williamson, Sean Bobbitt, Kevin Chitale, Dhananjay A. Tang, Deliang Rundle, Andrew G. Iczkowski, Kenneth A. |
author_sort | Rybicki, Benjamin A. |
collection | PubMed |
description | Growth and differentiation factor 15 (GDF‐15), also known as macrophage inhibitory cytokine 1 (MIC‐1), may act as both a tumor suppressor and promotor and, by regulating NF‐κB and macrophage signaling, promote early prostate carcinogenesis. To determine whether expression of these two inflammation‐related proteins affect prostate cancer susceptibility, dual immunostaining of benign prostate biopsies for GDF‐15 and NF‐κB was done in a study of 503 case‐control pairs matched on date, age, and race, nested within a historical cohort of 10,478 men. GDF‐15 and NF‐κB expression levels were positively correlated (r = 0.39; p < 0.0001), and both were significantly lower in African American (AA) compared with White men. In adjusted models that included both markers, the odds ratio (OR) for NF‐κB expression was statistically significant, OR =0.87; p = 0.03; 95% confidence interval (CI) =0.77–0.99, while GDF‐15 expression was associated with a nominally increased risk, OR =1.06; p = 0.27; 95% CI =0.96–1.17. When modeling expression levels by quartiles, the highest quartile of NF‐κB expression was associated with almost a fifty percent reduction in prostate cancer risk (OR =0.51; p = 0.03; 95% CI =0.29–0.92). In stratified models, NF‐κB had the strongest negative association with prostate cancer in non‐aggressive cases (p = 0.03), older men (p = 0.03), and in case‐control pairs with longer follow‐up (p = 0.02). Risk associated with GDF‐15 expression was best fit using nonlinear regression modeling where both first (p = 0.02) and second (p = 0.03) order GDF‐15 risk terms were associated with significantly increased risk. This modeling approach also revealed significantly increased risk associated with GDF‐15 expression for subsamples defined by AA race, aggressive disease, younger age, and in case‐control pairs with longer follow‐up. Therefore, although positively correlated in benign prostatic biopsies, NF‐κB and GDF‐15 expression appear to exert opposite effects on risk of prostate tumor development. |
format | Online Article Text |
id | pubmed-8085972 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | John Wiley and Sons Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-80859722021-05-07 Growth and differentiation factor 15 and NF‐κB expression in benign prostatic biopsies and risk of subsequent prostate cancer detection Rybicki, Benjamin A. Sadasivan, Sudha M. Chen, Yalei Kravtsov, Oleksandr Palangmonthip, Watchareepohn Arora, Kanika Gupta, Nilesh S. Williamson, Sean Bobbitt, Kevin Chitale, Dhananjay A. Tang, Deliang Rundle, Andrew G. Iczkowski, Kenneth A. Cancer Med Clinical Cancer Research Growth and differentiation factor 15 (GDF‐15), also known as macrophage inhibitory cytokine 1 (MIC‐1), may act as both a tumor suppressor and promotor and, by regulating NF‐κB and macrophage signaling, promote early prostate carcinogenesis. To determine whether expression of these two inflammation‐related proteins affect prostate cancer susceptibility, dual immunostaining of benign prostate biopsies for GDF‐15 and NF‐κB was done in a study of 503 case‐control pairs matched on date, age, and race, nested within a historical cohort of 10,478 men. GDF‐15 and NF‐κB expression levels were positively correlated (r = 0.39; p < 0.0001), and both were significantly lower in African American (AA) compared with White men. In adjusted models that included both markers, the odds ratio (OR) for NF‐κB expression was statistically significant, OR =0.87; p = 0.03; 95% confidence interval (CI) =0.77–0.99, while GDF‐15 expression was associated with a nominally increased risk, OR =1.06; p = 0.27; 95% CI =0.96–1.17. When modeling expression levels by quartiles, the highest quartile of NF‐κB expression was associated with almost a fifty percent reduction in prostate cancer risk (OR =0.51; p = 0.03; 95% CI =0.29–0.92). In stratified models, NF‐κB had the strongest negative association with prostate cancer in non‐aggressive cases (p = 0.03), older men (p = 0.03), and in case‐control pairs with longer follow‐up (p = 0.02). Risk associated with GDF‐15 expression was best fit using nonlinear regression modeling where both first (p = 0.02) and second (p = 0.03) order GDF‐15 risk terms were associated with significantly increased risk. This modeling approach also revealed significantly increased risk associated with GDF‐15 expression for subsamples defined by AA race, aggressive disease, younger age, and in case‐control pairs with longer follow‐up. Therefore, although positively correlated in benign prostatic biopsies, NF‐κB and GDF‐15 expression appear to exert opposite effects on risk of prostate tumor development. John Wiley and Sons Inc. 2021-03-30 /pmc/articles/PMC8085972/ /pubmed/33784024 http://dx.doi.org/10.1002/cam4.3850 Text en © 2021 The Authors. Cancer Medicine published by John Wiley & Sons Ltd. https://creativecommons.org/licenses/by/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Clinical Cancer Research Rybicki, Benjamin A. Sadasivan, Sudha M. Chen, Yalei Kravtsov, Oleksandr Palangmonthip, Watchareepohn Arora, Kanika Gupta, Nilesh S. Williamson, Sean Bobbitt, Kevin Chitale, Dhananjay A. Tang, Deliang Rundle, Andrew G. Iczkowski, Kenneth A. Growth and differentiation factor 15 and NF‐κB expression in benign prostatic biopsies and risk of subsequent prostate cancer detection |
title | Growth and differentiation factor 15 and NF‐κB expression in benign prostatic biopsies and risk of subsequent prostate cancer detection |
title_full | Growth and differentiation factor 15 and NF‐κB expression in benign prostatic biopsies and risk of subsequent prostate cancer detection |
title_fullStr | Growth and differentiation factor 15 and NF‐κB expression in benign prostatic biopsies and risk of subsequent prostate cancer detection |
title_full_unstemmed | Growth and differentiation factor 15 and NF‐κB expression in benign prostatic biopsies and risk of subsequent prostate cancer detection |
title_short | Growth and differentiation factor 15 and NF‐κB expression in benign prostatic biopsies and risk of subsequent prostate cancer detection |
title_sort | growth and differentiation factor 15 and nf‐κb expression in benign prostatic biopsies and risk of subsequent prostate cancer detection |
topic | Clinical Cancer Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8085972/ https://www.ncbi.nlm.nih.gov/pubmed/33784024 http://dx.doi.org/10.1002/cam4.3850 |
work_keys_str_mv | AT rybickibenjamina growthanddifferentiationfactor15andnfkbexpressioninbenignprostaticbiopsiesandriskofsubsequentprostatecancerdetection AT sadasivansudham growthanddifferentiationfactor15andnfkbexpressioninbenignprostaticbiopsiesandriskofsubsequentprostatecancerdetection AT chenyalei growthanddifferentiationfactor15andnfkbexpressioninbenignprostaticbiopsiesandriskofsubsequentprostatecancerdetection AT kravtsovoleksandr growthanddifferentiationfactor15andnfkbexpressioninbenignprostaticbiopsiesandriskofsubsequentprostatecancerdetection AT palangmonthipwatchareepohn growthanddifferentiationfactor15andnfkbexpressioninbenignprostaticbiopsiesandriskofsubsequentprostatecancerdetection AT arorakanika growthanddifferentiationfactor15andnfkbexpressioninbenignprostaticbiopsiesandriskofsubsequentprostatecancerdetection AT guptanileshs growthanddifferentiationfactor15andnfkbexpressioninbenignprostaticbiopsiesandriskofsubsequentprostatecancerdetection AT williamsonsean growthanddifferentiationfactor15andnfkbexpressioninbenignprostaticbiopsiesandriskofsubsequentprostatecancerdetection AT bobbittkevin growthanddifferentiationfactor15andnfkbexpressioninbenignprostaticbiopsiesandriskofsubsequentprostatecancerdetection AT chitaledhananjaya growthanddifferentiationfactor15andnfkbexpressioninbenignprostaticbiopsiesandriskofsubsequentprostatecancerdetection AT tangdeliang growthanddifferentiationfactor15andnfkbexpressioninbenignprostaticbiopsiesandriskofsubsequentprostatecancerdetection AT rundleandrewg growthanddifferentiationfactor15andnfkbexpressioninbenignprostaticbiopsiesandriskofsubsequentprostatecancerdetection AT iczkowskikennetha growthanddifferentiationfactor15andnfkbexpressioninbenignprostaticbiopsiesandriskofsubsequentprostatecancerdetection |